trending Market Intelligence /marketintelligence/en/news-insights/trending/oVlhdfTllW1czaoebdFZwg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neuren Pharmaceuticals' therapy for genetic conditions granted US FDA orphan tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Neuren Pharmaceuticals' therapy for genetic conditions granted US FDA orphan tag

Neuren Pharmaceuticals Ltd. said the U.S. Food and Drug Administration classified its therapy NNZ-2591 as an orphan drug for treating three genetic conditions.

NNZ-2591 is being developed to treat Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome.

SNL Image

In patients with Angelman syndrome, the ubiquitin protein ligase E3A gene on chromosome 15 is either missing or mutated. The complex genetic disorder, which mainly affects the nervous system, causes development delays and learning disabilities.

Phelan-McDermid syndrome is caused by a deletion or other change in the 22q13 region of chromosome 22 and is characterized by intellectual disability, speech impairment, low muscle tone and epilepsy, among other things.

Patients with Pitt Hopkins syndrome lack a copy of or have a mutated TCF4 gene on chromosome 18. They experience breathing problems, recurrent seizures, gastrointestinal problems and sleep disturbance.

There are no approved therapies for the three genetic conditions, the Australian drugmaker said.

Medicines classified by the FDA as orphan are those intended to treat rare conditions that affect fewer than 200,000 people in the U.S. They receive various development incentives from the regulator, including tax credits and an extended period of exclusivity.